Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Artelo Biosciences Inc ARTL

Healthcare
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid agonist for the G protein-coupled receptor (GPCR) that targets a synthetic small molecule program, ART27.13, as a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder. In addition, the Company is also developing ART12.11 (CBD cocrystal), a solid-state composition of cannabidiol (CBD).


NDAQ:ARTL - Post by User

Artelo Biosciences Inc
<< Previous
 Bullboard Posts
User Avatar Image
(88)
•••
Post by whytestockson Feb 15, 2024 10:00pm
28 Views
Post# 35883374

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap
Just In: $ARTL Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thSOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it w...ARTL - Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities